# Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)

Study · id `cardio:ct-nct04075981` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04075981](<https://clinicaltrials.gov/study/NCT04075981>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04075981

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 220 participants.

## Technical summary

Registry record NCT04075981. Randomized; triple masking; primary purpose treatment. Start 2019-09-30 (actual); primary completion 2025-10-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT04075981, source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)
- Started: 2019-09-30 (actual) (ClinicalTrials.gov record NCT04075981, source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)
- Primary completion: 2025-10-13 (actual) (ClinicalTrials.gov record NCT04075981, source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)
- Completion: 2026-09-22 (anticipated) (ClinicalTrials.gov record NCT04075981, source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT04075981, source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04075981-2026-07-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF)
- Acronym: BOTAF
- Condition: Cardiac Surgery
- Intervention (Drug): Botulinum Toxin Type A Injection \[Xeomin\]
- Intervention (Other): Drug placebo
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Merz Pharmaceuticals
- Collaborator class: INDUSTRY
- Collaborator: Ministry of Health, France
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Ministry of Health, France (`cardio:org-ministry-of-health-france`)

## Provenance

Content hash: bb8c495249ddc6c0a69903bc0ecedadf2637b4eb274f2523c0a2e95d2af2cba1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
